Evotec Faces a Tightrope Walk as Cash Reserves Meet Restructuring Costs
Published on 07/18/2026 at 17:25 | Redaktion boerse-global.de
The biotech group Evotec has entered a period of heightened uncertainty after issuing a steep downgrade to its 2026 annual forecast alongside preliminary first-half results that fell sharply short of expectations. The company now projects full-year adjusted EBITDA losses ranging from €70 million to €105 million, and group revenue between €570 million and €610 million. At constant exchange rates, the revenue forecast narrows to €595-635 million and the EBITDA shortfall to €60-90 million. The warning, delivered via ad-hoc disclosure, marks the second time in roughly four months that Evotec has slashed its targets — an erosion of credibility that has driven the stock down 29.4% in just seven trading sessions to €3.50, barely above its 52-week low of €3.19.
The severity of the revision is underscored by the preliminary half-year numbers themselves. Revenue for the first six months came in at around €300.1 million, while adjusted EBITDA swung to a loss of €42.7 million. Yet the company still holds a liquidity buffer of €465.6 million as of June 30, and management insists this is sufficient to fund a restructuring that carries total cash costs of roughly €100 million through 2028. The key question for investors is whether that cushion will prove adequate before the cost-saving measures start generating tangible benefits — and the answer will not come until the audited half-year report is published on August 13, 2026.
Behind the headline pain, the operational picture is more nuanced. Evotec’s core business in Discovery & Preclinical Development — excluding strategic partnerships — posted net sales growth of over 28% in the first half, while its subsidiary Just – Evotec Biologics benefited from high utilisation rates and an expanding client base. The company also reiterated its “Horizon” cost-reduction programme, which targets €75 million in annual savings by the end of 2027, with 20-30% of that goal expected to be achieved in the current year. Management struck a confident tone, stating that the pipeline is “more active than ever” and that advanced talks are underway with established partners across high-need areas such as renal disease, oncology, women’s health and obesity.
Should investors sell immediately? Or is it worth buying Evotec?
Analyst reception to the guidance cut has been remarkably divided. Deutsche Bank and Berenberg both maintained “Hold” ratings, with price targets of €3.50 and €3.60 respectively. TD Cowen also kept a “Hold” but set a higher target of €4.00. Bank of America took a notably more bearish stance, downgrading the stock to “Underperform” with a target of just $2.40. At the opposite end, RBC Capital Markets analyst Charles Weston retained his “Outperform” rating, slashing his price objective to €10.00 from a prior higher level but arguing that the underlying growth in early-stage drug discovery still justifies a premium. The wide dispersion in analyst views — a spread of more than €7 between the most optimistic and most pessimistic targets — reflects deep disagreement over whether the partnership delays are a temporary timing issue or a sign of systemic weakness.
Technically, the stock appears severely oversold, with the 14-day relative strength index at 22.6. That reading has historically preceded short-term bounces in beaten-down names, but it offers no assurance about the underlying business health. The shares closed on Friday at €3.50, about 9.6% above their recent nadir, after edging up 1.22% on the day — a tentative recovery that may prove fragile.
Ultimately, the August 13 report will be the next major catalyst. It will reveal whether the preliminary figures hold up under audit, how quickly cash is being consumed, and whether management can offer more concrete evidence that the promised partnership deals are materialising. If the core business continues to grow and the liquidity position remains stable, Evotec may be granted the time it needs to execute its turnaround. But if the cash burn accelerates or another partnership delay emerges, the bear case — that repeated target misses have permanently damaged confidence — could quickly take hold. For now, the company is walking a tightrope, and its next step will determine whether the safety net holds.
Ad
Evotec Stock: New Analysis - 18 July
Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
